A PHASE I/II STUDY OF AKR1C3-ACTIVATED PRODRUG OBI8208;3424 (OBI-3424) IN PATIENTS WITH RELAPSED/REFRACTORY TCELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) / T-CELL LYMPHOBLASTIC LYMPHOMA (T-LBL)